IL-17A in the tumor microenvironment of the human colorectal adenomacarcinoma sequence

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 11, 2012, Pages 1304-1312

  Cui, Guanglin ^a,b   Yuan, Aping ^a,b   Goll, Rasmus ^b   Florholmen, Jon ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Carcinogenesis; Colorectum; Interleukin 17; Tumor microenvironment

Indexed keywords

INTERLEUKIN 17; MESSENGER RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASIA; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TH17 CELL; TUMOR MICROENVIRONMENT;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-23; INTERLEUKIN-6; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84867526156     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.725089     Document Type: Article

References (47)

1. Fearon ER. Molecular genetic studies of the adenoma-carcinoma sequence. Adv Intern Med 1994;39:123-47.
2. Cho KR, Vogelstein B. Genetic alterations in the adenomacarcinoma sequence. Cancer 1992;70:1727-31.
3. Contasta I, Berghella AM, Pellegrini P, Adorno D. Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 2003;18: 549-57. (Pubitemid 37082374)
4. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66: 605-12. (Pubitemid 43165918)
5. Cui G, Goll R, Olsen T, Steigen SE, Husebekk A, Vonen B, et al. Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother 2007;56: 985-95. (Pubitemid 46675303)
6. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005;28:187-96.
7. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 2008;9: 375-80. (Pubitemid 352025211)
8. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008;68: 323-8. (Pubitemid 351380135)
9. Cui G, Yuan A, Goll R, Vonen B, Florholmen J. Dynamic changes of interleukin-8 network along the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother 2009;58:1897-905.
10. Xu T, Sun BC, Li Q, Hao XS. Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells. World J Gastroenterol 2005;11:3915-19. (Pubitemid 41025248)
11. Cui G, Yuan A, Goll R, Vonen B, Florholmen J. Dynamic changes of interleukin-8 network along the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother 2009;58:1897-905.
12. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
13. Maniati E, Soper R, Hagemann T. Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 2010;29: 5653-62.
14. Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011;56: 633-40.
15. Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol 2012;47:538-47.
16. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;119: 3011-23.
17. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 2010;184: 2281-8.
18. Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs 2009;10:543-9.
19. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009;183:4169-75.
20. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-73.
21. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-9.
22. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-7. (Pubitemid 36857622)
23. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011; 407:348-54.
24. Yang S, Wang B, Guan C, Wu B, Cai C, Wang M, et al. Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol 2011;89: 85-91.
25. Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O, Bothwell AL. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA 2010;107:5540-4.
26. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-22.
27. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68: 3915-23.
28. Hyun YS, Han DS, Lee AR, Eun CS, Youn J, Kim HY. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 2012;33(4):931-6.
29. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008;57:772-9. (Pubitemid 351716970)
30. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71: 1263-71.
31. Cui G, Yuan A, Vonen B, Florholmen J. Progressive cellular response in the lamina propria of the colorectal adenoma-carcinoma sequence. Histopathology 2009;54: 550-60.
32. Ivanov II, Zhou L, Littman DR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol 2007;19: 409-17. (Pubitemid 351274050)
33. Dong C. Differentiation and function of pro-inflammatory Th17 cells. Microbes Infect 2009;11:584-8.
34. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009;114:357-9.
35. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65-70. (Pubitemid 36020767)
36. Nielsen OH, Kirman I, Rudiger N, Hendel J, Vainer B. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol 2003;38: 180-5. (Pubitemid 36349930)
37. Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles C, Rampton DS, et al. Differential regulation of interleukin-17-and interferon-{gamma} production in inflammatory bowel disease. Gut 2009;58:1629-36.
38. Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009;15: 1090-100.
39. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg 2002;89:845-60. (Pubitemid 34779568)
40. Wågsäter D, Lofgren S, Hugander A, Dimberg J. Expression of interleukin-17 in human colorectal cancer. Anticancer Res 2006;26:4213-16. (Pubitemid 46031493)
41. Fox SH, Whalen GF, Sanders MM, Burleson JA, Jennings K, Kurtzman S, et al. Angiogenesis in normal tissue adjacent to colon cancer. J Surg Oncol 1998;69:230-4. (Pubitemid 29024567)
42. Pandey S, Gordon PH, Wang E. Expression of proliferation-specific genes in the mucosa adjacent to colon carcinoma. Dis Colon Rectum 1995;38:462-7.
43. Cui G, Yuan A, Goll R, Olsen T, Husebekk A, Vonen B, et al. Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother 2007;56:1993-2001. (Pubitemid 47512619)
44. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999;59:3698-704. (Pubitemid 29381875)
45. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206: 1457-64.
46. Inozume T, Hanada K, Wang QJ, Yang JC. IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J Immunother 2009;32:109-17.
47. Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One 2012;7:e34959.